Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam plus alfentanil vs remimazolam plus remifentanil for painless bronchoscopy
ChiCTR2600124376Phase 4Not yet recruiting
- Sponsor
- Wuhan Central Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in procedural pain and Procedural anxiety comparing Control: remimazolam + remifentanil with remimazolam + alfentanil (2 arms). Primary endpoints: Incidence of bronchospasm or laryngospasm and Cough score (VAS). Planned start May 2026; status: not yet recruiting.
02
Drugs
remimazolamalfentanilremifentanil
03
Conditions
procedural painProcedural anxiety
Beyond the preview
Go deeper on ChiCTR2600124376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124376.